| Stage | JNJ | % of rev | LLY | % of rev | Gap · A − B |
|---|---|---|---|---|---|
| Revenue | $25.4B | 100.00% | $24.4B | 100.00% | JNJ ×1.04 |
| Gross profit | $17.3B | 68.12% | $20.5B | 83.88% | LLY +15.8pp |
| Operating income | $5.8B | 23.01% | $8.6B | 35.28% | LLY +12.3pp |
| Pre-tax income | $34M | 0.13% | $8.4B | 34.46% | LLY +34.3pp |
| Net income | $210M | 0.83% | $6.5B | 26.44% | LLY +25.6pp |
| Stage | JNJ | LLY | Gap · A − B |
|---|---|---|---|
| Revenue | $25.4B100.00% | $24.4B100.00% | JNJ ×1.04 |
| Gross profit | 68.12%$17.3B | 83.88%$20.5B | LLY +15.8pp |
| Operating income | 23.01%$5.8B | 35.28%$8.6B | LLY +12.3pp |
| Pre-tax income | 0.13%$34M | 34.46%$8.4B | LLY +34.3pp |
| Net income |
| 0.83%$210M |
| 26.44%$6.5B |
| LLY +25.6pp |
JNJ · AVTX 10-KMar 23 '26
“The economic rights sold include (a) rights to a milestone payment of $20.0 million upon the filing and acceptance of an NDA for AVTX-501 pursuant to an agreement with Janssen Pharmaceutics, Inc., now Johnson & Johnson Innovative Medicine ("J&J") (the "AVTX-501 Milestone") and (b) rights to any future milestone payments and royalties relating to AVTX-007 under a license agreement with Apollo AP43 Limited ("Apollo"), including up to $6.25 million of development milestones, up to $67.5 million in sales-based milestones, and royalty payments over a ten year period of a low single digit percentage of annual net sales (which percentage increases to another low single digit percentage if annual net sales exceed a specified threshold) (the "AVTX-007 Milestones and Royalties").”
“Abdakibart (AVTX-009) is subject to a world-wide exclusive license from Eli Lilly and Company ("Lilly") (the "Lilly License Agreement"), as well as an agreement under which AlmataBio, Inc. ("AlmataBio") purchased rights to the compound from Leap Therapeutics, Inc. ("Leap" and the "Leap Agreement").”
JNJ · MGTX 10-KMar 30 '26
“MeiraGTx UK II Limited and Johnson & Johnson Innovative Medicine also entered into a Supply Agreement on the Closing Date pursuant to which MeiraGTx UK II Limited agreed to manufacture and supply the RPGR Product for Johnson & Johnson Innovative Medicine (the "Supply Agreement").”
LLY · MGTX 10-KMar 30 '26
“On November 7, 2025 (the "Effective Date"), our affiliates MeiraGTx Ocular UK Limited ("MeiraGTx Ocular"), MeiraGTx Limited and MeiraGTx UK II Limited, entered into a strategic collaboration and license agreement with Eli Lilly and Company ("Lilly") (the "Lilly Collaboration Agreement") for the research, development and commercialization of genetic medicines in and related to the area of ophthalmology.”
JNJ · VNDA 10-KFeb 12 '26
“PONVORY ® tablets were approved in the U.S. for the treatment of RMS in adults in March 2021 and commercially launched in the U.S. by Actelion Pharmaceuticals Ltd. (Janssen), a Johnson & Johnson Company in April 2021.”
LLY · VNDA 10-KFeb 12 '26
“In April 2012, we entered into a license agreement with Eli Lilly and Company (Lilly) pursuant to which we acquired an exclusive worldwide license under certain patents and patent applications, and other licenses to intellectual property, to develop and commercialize NEREUS TM for all human indications.”
JNJ · ACIU 20-FMar 13 '26
“In December 2014, we entered into an agreement with Janssen Pharmaceuticals, Inc. (Janssen), part of a Johnson & Johnson company, to develop and commercialize therapeutic anti-Tau active immunotherapies for the treatment of AD and potentially other tauopathies.”
LLY · ACIU 20-FMar 13 '26
“In December 2018, we entered into an exclusive, worldwide licensing agreement with Eli Lilly and Company (Lilly) to research and develop Morphomer Tau small molecules for the treatment of AD and other neurodegenerative diseases. Per the terms of the agreement, the Company received an initial upfront payment of CHF 80 million in Q1 2019 for the rights granted by the Company to Lilly.”